Agreement - July 7, 2015
Heptares and AstraZeneca sign agreement
Heptares Therapeutics, a clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking […]
Collaboration - July 7, 2015
Astra Forms New Partnerships
AstraZeneca is involved in two new projects that focus on heart disease and respiratory illness. The company is partnering with the Montreal Heart Institute, which will search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes. AstraZeneca also has reached a new deal with Abbott Laboratories for a diagnostic […]
In a new job - June 24, 2015
Astra CMO Quits Suddenly
AstraZeneca’s chief medical officer suddenly left his job Wednesday to become the chief executive officer of an unnamed, smaller biotech company, according to BioSpace.com. Briggs Morrison, AstraZeneca’s chief medical officer and head of global late-stage drug development, is scheduled to leave immediately. The company notified his colleagues prior to the announcement, BioSpace.com said. “It’s a great […]
New Market - June 8, 2015
AZ’s Interest in Immuno-oncology Grows
AstraZeneca and Medimmune, AstraZeneca PLC’s global biologics research and development unit, gave a presentation on the company’s pipeline in the area of immuno-oncology at the recent American Society of Clinical Oncology meeting. Immuno-oncology involves programming or stimulating the body’s own immune system to attack cancer cells, according to BioSpace.com. The companies reported on a number of pipeline […]
Companies - June 5, 2015
AZ Pondering Future of Psoriasis Drug
AstraZeneca will need to decide soon whether to independently pursue an experimental psoriasis drug that has been linked to suicidal side effects, Bloomberg reported recently. “We want to take more time to look at the data and take time to engage with regulators,” AstraZeneca’s Chief Executive Officer Pascal Soriot told the news service about brodalumab. “We are actively contacting people who […]
Acquisition - May 29, 2015
Olympian Promoting OIC Awareness
AstraZeneca and Daiichi Sankyo have partnered with six-time Olympic medalist Jackie Joyner-Kersee to increase awareness of opioid-induced constipation (OIC). Joyner-Kersee speaks candidly about her struggle with OIC after taking opioid medication prescribed by her healthcare provider to help manage pain stemming from years of training to compete in the long jump and heptathlon. She earned […]
